title: Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia.
abstract: Severe persistent pulmonary hypertension of the newborn (PPHN) remains a significant cause of neonatal morbidity and mortality with limited effective treatment options. We present the first case of a neonate with PPHN treated concurrently with inhaled nitric oxide (iNO) and intravenous prostacyclin (PGI2). He ultimately was diagnosed with alveolar-capillary dysplasia, a rare and fatal cause of pulmonary hypertension. However, his partial response to treatment demonstrates a possible role for combined therapy with iNO and PGI2 in infants with severe PPHN.
authors.affiliation: Department of Pediatrics, University of Colorado School of Medicine, The Children's Hospital, Denver, USA.
authors.forename: T A
authors.initials: TA
authors.lastname: Parker
authors.forename: D D
authors.initials: DD
authors.lastname: Ivy
authors.forename: J P
authors.initials: JP
authors.lastname: Kinsella
authors.forename: F
authors.initials: F
authors.lastname: Torielli
authors.forename: S Z
authors.initials: SZ
authors.lastname: Ruyle
authors.forename: E H
authors.initials: EH
authors.lastname: Thilo
authors.forename: S H
authors.initials: SH
authors.lastname: Abman
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004452:Echocardiography; D011464:Epoprostenol / Q000008:administration & dosage*; D017809:Fatal Outcome; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D009569:Nitric Oxide / Q000008:administration & dosage*; D011651:Pulmonary Artery / Q000002:abnormalities; D011667:Pulmonary Veins / Q000002:abnormalities
chemical_list: D000959:Antihypertensive Agents; D009569:Nitric Oxide; D011464:Epoprostenol